For the third quarter of FY2023,JAZZ PHARMACEUTICALS ($NASDAQ:JAZZ) reported total revenue of USD 972.1 million; an increase of 3.3% compared to the same quarter of the previous year. Net income was reported to be an impressive USD 146.8 million, in stark contrast to the negative -19.6 million posted in the same quarter of the previous year.
On Wednesday, JAZZ PHARMACEUTICALS reported its third quarter earnings results for FY2023. The stock opened at $134.3 and closed at $128.2, down by 4.1% from the prior closing price of 133.7. The decline in JAZZ PHARMACEUTICALS’ market price reflects the overall performance of the company’s third quarter earnings report. These figures demonstrate the continued success and growth of JAZZ PHARMACEUTICALS and reaffirm the potential of the company for long-term success. In addition to financial results, JAZZ PHARMACEUTICALS announced plans to invest heavily in research and development, as well as in new products and services.
The company is looking to expand its portfolio of drugs and treatments in order to meet the needs of a growing patient population. With this investment, the company is looking to further its efforts to improve patient outcomes and provide better healthcare solutions. Overall, JAZZ PHARMACEUTICALS had a successful third quarter, and investors are hopeful that the company will continue to build upon its success over the coming quarters. With its commitment to innovation and patient-focused solutions, JAZZ PHARMACEUTICALS is well positioned to remain competitive in the rapidly evolving pharmaceutical industry. Live Quote…
About the Company
Ownership (Institutional/ Fund Holdings)
Below shows the total revenue, net income and net margin for Jazz Pharmaceuticals. More…
Income Statement Reports (Yearly/ Quarterly/ LTM)
Cash Flow Snapshot
Below shows the cash from operations, investing and financing for Jazz Pharmaceuticals. More…
Cash Flow Statement (Yearly/ Quarterly/ LTM)
Cash Flow Supplement
Balance Sheet Snapshot
Below shows the total assets, liabilities and book value per share for Jazz Pharmaceuticals. More…
Balance Sheet (Yearly/ Quarterly)
Balance Sheet Supplement
||Book Value Per Share
Key Ratios Snapshot
Some of the financial key ratios for Jazz Pharmaceuticals are shown below. More…
Income Statement Ratios
Balance Sheet Ratios
Cash Flow Ratios
Other Supplementary Items
|3Y Rev Growth
||3Y Operating Profit Growth
Analysis – Jazz Pharmaceuticals Intrinsic Stock Value
GoodWhale’s analysis of the fundamentals of JAZZ PHARMACEUTICALS has uncovered a fair value of $170.0 for its shares. This calculation was made using our proprietary Valuation Line which takes into consideration the company’s earnings, dividends, growth potential and other key financial metrics. Currently, JAZZ PHARMACEUTICALS’ stock is trading at $128.2, representing a 24.6% discount to its fair value. This presents a potentially attractive buying opportunity for investors looking to capitalize on the mispricing of the stock at this time. More…
Star Chart Analysis
The company has a diversified portfolio of products in central nervous system, hematology/oncology, inflammation and other therapeutic areas. Jazz Pharmaceuticals‘ competitors include Nurix Therapeutics Inc, Incyte Corp, and Poxel SA.
– Nurix Therapeutics Inc ($NASDAQ:NRIX)
Nurix Therapeutics Inc. is a clinical-stage biopharmaceutical company, which focuses on harnessing the body’s own natural mechanisms to regulate protein function for the treatment of cancer and other diseases. The company’s lead product candidate is a first-in-class, orally available, small molecule inhibitor of the proteasome, which is in development for the treatment of relapsed or refractory multiple myeloma. Nurix was founded by Robert L. Gould, Ph.D. and Bruce A. Cohen, M.D. in December 2001 and is headquartered in San Francisco, CA.
Incyte Corp is a biopharmaceutical company that focuses on the discovery, development, and commercialization of proprietary therapeutics to treat serious unmet medical needs, primarily in oncology. The company’s market cap is 15.34B as of 2022 and its ROE is 9.54%. Incyte’s products include Jakafi, Iclusig, and Jakavi. Jakafi is used to treat myelofibrosis and polycythemia vera, two rare blood disorders. Iclusig is used to treat leukemias, including chronic myeloid leukemia andPhiladelphia chromosome-positive acute lymphoblastic leukemia. Jakavi is used to treat myelofibrosis, polycythemia vera, and essential thrombocythemia.
Poxel SA is a French pharmaceutical company that focuses on the development and commercialization of drugs for the treatment of diabetes and obesity. The company has a market capitalization of 43.37 million as of 2022 and a return on equity of -705.2%. Poxel SA’s products include Imeglimin, which is in clinical development for the treatment of type 2 diabetes, and PXL065, which is in preclinical development for the treatment of obesity.
Jazz Pharmaceuticals reported strong financial results for the third quarter of FY2023, with total revenue up 3.3% year-over-year to USD 972.1 million and net income of USD 146.8 million, a significant improvement over the negative -19.6 million reported in the same quarter of the prior year. Despite this positive news, the company’s stock price moved down on the same day. Investors may be concerned about the long-term outlook for the company, but Jazz Pharmaceuticals’ strong financial results indicate that it could be a good opportunity for investors looking for a safe investment with potential upside.